How to accelerate the use of iPSCs in drug development

Flow cytometers, droplet dispensers, and limiting dilution techniques aimed at depositing a single iPSC in a well, often create a strenuous and unnatural environment that leads to low clonal survival efficiency.   

The CellRaft® Array provides a more biologically relevant culture environment by offering flask-like culture conditions combined with single-cell segregation, enabling tens of thousands of cells per consumable.

Given the unique capability of the CellRaft AIR® System to identify CellRafts containing specific numbers of cells at different time points, the researchers aimed to compare the efficiency of clonal formation when isolating cells at various stages along the exponential growth curve. The objective was to determine whether isolating a colony instead of a single cell could improve the success rates and efficiency of single-cell cloning workflows.  

Benefits of the CellRaft AIR® System:

  • Generate 100s of monoclonal iPSC lines in under two weeks
  • Achieve >90% clonal outgrowth by isolating monoclonal colonies
  • Enable all iPSC workflows from reprogramming to differentiation on one consumable
  • Optimize iPSCs for 2D and 3D culture

Methods

How to accelerate the use of iPSCs in drug development

Image Credit: Cell Microsystems

Results

Only 10% of single iPSCs formed viable monoclonal colonies in the limiting dilution technique. Similarly, when using CellRaft technology at the single-cell stage of iPSC cell expansion, only 10% of the wells in the 96-well plates contained viable clones.  

By isolating CellRafts at the four-cell and colony stages, the clonal outgrowth of iPSCs increased significantly to 87% and 98%, respectively.  

Allowing the single cells to continue growing undisturbed in a shared microenvironment before colony isolation optimized the outgrowth efficiency, eliminating it as a limiting factor in cell line development workflows.  

CellRaft technology supports various iPSC workflows, including the expansion of single cells, differentiation into different cell types or tissue-specific organoids, characterization of fluorescent expression or stained cells, and reprogramming human fibroblasts into iPSCs.  

How to accelerate the use of iPSCs in drug development

Image Credit: Cell Microsystems

Single human iPSCs were directly seeded onto an uncoated 200 µM Single CellRaft Array in dilute iMatrix-511 (Matrixome) at a density of 5:1 (cells: rafts). For example, limiting dilution plates were seeded at 1 cell/well thickness in five 96-well plates pre-coated with h-ESC Matrigel. 

iPSCs on CellRaft® arrays

How to accelerate the use of iPSCs in drug development

Image Credit: Cell Microsystems

Overnight in the incubator, a 200 m Single CellRaft Array was covered with iMatrix-511. GFP-labeled iPSCs were planted in mTesR Plus, dilute iMatrix-511, and different additives at a ratio of 5 cells per CellRaft. The array was serially scanned daily, and CellRafts with monoclonal colonies were separated utilizing the CellRaft AIR® System. 

How to accelerate the use of iPSCs in drug development

Image Credit: Cell Microsystems

In varied dilute concentrations of common matrices, iPSCs were seeded onto a 200 m Quad CellRaft Array. The CellRaft AIR System was used to identify and isolate single cell-derived iPSC colonies. 

iPSC single cell expansion

How to accelerate the use of iPSCs in drug development

Image Credit: Cell Microsystems

iPSCs were seeded in dilute iMatrix511 onto a 200 m Quad CellRaft Array. The array was sequentially scanned daily for three days to assess the effectiveness of clonal formation of iPSCs separated at various points along the exponential development curve to determine the best stage for dependable colony expansion.

How to accelerate the use of iPSCs in drug development

Image Credit: Cell Microsystems

The outgrowth efficiency of isolated CellRafts containing single iPSC-expanded cells was observed and compared with the limiting dilution plates.

How to accelerate the use of iPSCs in drug development

Image Credit: Cell Microsystems

The CellRaft Array was photographed four hours after seeding to detect CellRafts harboring iPSCs. CellRafts at various stages of development were isolated throughout the following three days. For one week after isolation, colony expansion was evaluated. 

iPSC differentiated organoids

How to accelerate the use of iPSCs in drug development

Image Credit: Cell Microsystems

Edited single iPSCs were differentiated to generate mono- and dual-fluorescent brain organoids on the 500 m CellRaft Array. RFP- and GFP-edited iPSCs were co-cultured in dilute ECM on the CellRaft Array for a week during embryoid body development and neural induction for choroid plexus organoid differentiation and photographed daily. 

Reprogram iPSCs

How to accelerate the use of iPSCs in drug development

Image Credit: Cell Microsystems

A 200 µm Single CellRaft Array and a 6-well plate were coated with dilute Geltrex. Human fibroblasts were transfected and seeded onto the array or the 6-well plate. Daily imaging was conducted for both the array and the 6-well plate. After 15 days, cells were live stained for Tra-1-60 before isolation to confirm the pluripotency of reprogrammed iPSC clones.

How to accelerate the use of iPSCs in drug development

Image Credit: Cell Microsystems

About Cell Microsystems

Making innovative tools that enable researchers to image, identify, and isolate viable single cells and clonal colonies

Researchers worldwide in the fields of CRISPR gene editing, oncology, stem cell biology, immunology and neurobiology use Cell Microsystems products, advancing sophisticated discovery across the life sciences.

The company’s CellRaft AIR® System addresses two widespread challenges facing scientists: the ability to actively select viable single cells or clonal colonies based on their phenotype, and match these cells to clonal expansion or molecular analyses. Cells are seeded, imaged, identified, and isolated on Cell Microsystem’s CellRaft® Arrays.

We have tested more than 100 Cell Lines with CellRaft Technology to demonstrate the high outgrowth efficiencies using our platform.

The company currently markets its products to researchers worldwide, and prides itself on being a customer-focused organization responsive to feedback and inspired to fuel deeper contributions to science.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Jul 12, 2023 at 12:46 PM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Cell Microsystems. (2023, July 12). How to accelerate the use of iPSCs in drug development. News-Medical. Retrieved on November 21, 2024 from https://www.news-medical.net/whitepaper/20230712/How-to-accelerate-the-use-of-iPSCs-in-drug-development.aspx.

  • MLA

    Cell Microsystems. "How to accelerate the use of iPSCs in drug development". News-Medical. 21 November 2024. <https://www.news-medical.net/whitepaper/20230712/How-to-accelerate-the-use-of-iPSCs-in-drug-development.aspx>.

  • Chicago

    Cell Microsystems. "How to accelerate the use of iPSCs in drug development". News-Medical. https://www.news-medical.net/whitepaper/20230712/How-to-accelerate-the-use-of-iPSCs-in-drug-development.aspx. (accessed November 21, 2024).

  • Harvard

    Cell Microsystems. 2023. How to accelerate the use of iPSCs in drug development. News-Medical, viewed 21 November 2024, https://www.news-medical.net/whitepaper/20230712/How-to-accelerate-the-use-of-iPSCs-in-drug-development.aspx.

Other White Papers by this Supplier

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.